Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
38
XTLB Quote, Financials, Valuation and Earnings
Last price:
$0.66
Seasonality move
:
20.53%
Day range:
$0.65 - $0.71
52-week range:
$0.65 - $2.57
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.98x
P/B ratio:
1.09x
Volume:
71.5K
Avg. volume:
44.9K
1-year change:
-67.48%
Market cap:
$5.9M
Revenue:
$453.1K
EPS (TTM):
-$0.20
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -- | -- | -- | -- |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $2.50 |
|
CGEN
Compugen Ltd.
|
$1.5M | -$0.09 | 10.1% | -9.81% | $6.25 |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-- | -$6.08 | -- | -66.65% | $399.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XTLB
XTL Biopharmaceuticals Ltd.
|
$0.67 | -- | $5.9M | -- | $0.00 | 0% | 11.98x |
|
CANF
Can-Fite BioPharma Ltd.
|
$0.17 | $2.50 | $2.7M | -- | $0.00 | 0% | 0.96x |
|
CGEN
Compugen Ltd.
|
$1.47 | $6.25 | $137.5M | 55.83x | $0.00 | 0% | 19.64x |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
PHGE
BiomX, Inc.
|
$2.00 | $399.00 | $3.1M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XTLB
XTL Biopharmaceuticals Ltd.
|
2.86% | -0.668 | 1.28% | 0.75x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.899 | -- | -- |
|
CGEN
Compugen Ltd.
|
6.3% | 2.845 | 2.14% | 4.24x |
|
NSRX
Nasus Pharma
|
-- | 0.000 | -- | -- |
|
PHGE
BiomX, Inc.
|
38.57% | 0.072 | 20.14% | 1.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -$764K | -33.97% | -34.34% | -283.95% | -- |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
XTL Biopharmaceuticals Ltd. vs. Competitors
-
Which has Higher Returns XTLB or CANF?
Can-Fite BioPharma Ltd. has a net margin of -341.36% compared to XTL Biopharmaceuticals Ltd.'s net margin of --. XTL Biopharmaceuticals Ltd.'s return on equity of -34.34% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About XTLB or CANF?
XTL Biopharmaceuticals Ltd. has a consensus price target of --, signalling upside risk potential of 4356.33%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 1357.73%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than Can-Fite BioPharma Ltd., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than Can-Fite BioPharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings XTLBXTL Biopharmaceuticals Ltd.0 0 0 CANFCan-Fite BioPharma Ltd.1 1 0 -
Is XTLB or CANF More Risky?
XTL Biopharmaceuticals Ltd. has a beta of 1.174, which suggesting that the stock is 17.404% more volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.756%.
-
Which is a Better Dividend Stock XTLB or CANF?
XTL Biopharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XTL Biopharmaceuticals Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XTLB or CANF?
XTL Biopharmaceuticals Ltd. quarterly revenues are $162K, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. XTL Biopharmaceuticals Ltd.'s net income of -$553K is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, XTL Biopharmaceuticals Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XTL Biopharmaceuticals Ltd. is 11.98x versus 0.96x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XTLBXTL Biopharmaceuticals Ltd.11.98x -- $162K -$553K CANFCan-Fite BioPharma Ltd.0.96x -- -- --
-
Which has Higher Returns XTLB or CGEN?
Compugen Ltd. has a net margin of -341.36% compared to XTL Biopharmaceuticals Ltd.'s net margin of -369.06%. XTL Biopharmaceuticals Ltd.'s return on equity of -34.34% beat Compugen Ltd.'s return on equity of -51.8%.
Company Gross Margin Earnings Per Share Invested Capital XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M CGENCompugen Ltd.12.75% -$0.07 $46.8M -
What do Analysts Say About XTLB or CGEN?
XTL Biopharmaceuticals Ltd. has a consensus price target of --, signalling upside risk potential of 4356.33%. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 325.17%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than Compugen Ltd., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings XTLBXTL Biopharmaceuticals Ltd.0 0 0 CGENCompugen Ltd.4 0 0 -
Is XTLB or CGEN More Risky?
XTL Biopharmaceuticals Ltd. has a beta of 1.174, which suggesting that the stock is 17.404% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.
-
Which is a Better Dividend Stock XTLB or CGEN?
XTL Biopharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XTL Biopharmaceuticals Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XTLB or CGEN?
XTL Biopharmaceuticals Ltd. quarterly revenues are $162K, which are smaller than Compugen Ltd. quarterly revenues of $1.9M. XTL Biopharmaceuticals Ltd.'s net income of -$553K is higher than Compugen Ltd.'s net income of -$7M. Notably, XTL Biopharmaceuticals Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XTL Biopharmaceuticals Ltd. is 11.98x versus 19.64x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XTLBXTL Biopharmaceuticals Ltd.11.98x -- $162K -$553K CGENCompugen Ltd.19.64x 55.83x $1.9M -$7M
-
Which has Higher Returns XTLB or NSRX?
Nasus Pharma has a net margin of -341.36% compared to XTL Biopharmaceuticals Ltd.'s net margin of --. XTL Biopharmaceuticals Ltd.'s return on equity of -34.34% beat Nasus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M NSRXNasus Pharma-- -- -- -
What do Analysts Say About XTLB or NSRX?
XTL Biopharmaceuticals Ltd. has a consensus price target of --, signalling upside risk potential of 4356.33%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than Nasus Pharma, analysts believe XTL Biopharmaceuticals Ltd. is more attractive than Nasus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings XTLBXTL Biopharmaceuticals Ltd.0 0 0 NSRXNasus Pharma0 0 0 -
Is XTLB or NSRX More Risky?
XTL Biopharmaceuticals Ltd. has a beta of 1.174, which suggesting that the stock is 17.404% more volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock XTLB or NSRX?
XTL Biopharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XTL Biopharmaceuticals Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XTLB or NSRX?
XTL Biopharmaceuticals Ltd. quarterly revenues are $162K, which are larger than Nasus Pharma quarterly revenues of --. XTL Biopharmaceuticals Ltd.'s net income of -$553K is higher than Nasus Pharma's net income of --. Notably, XTL Biopharmaceuticals Ltd.'s price-to-earnings ratio is -- while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XTL Biopharmaceuticals Ltd. is 11.98x versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XTLBXTL Biopharmaceuticals Ltd.11.98x -- $162K -$553K NSRXNasus Pharma-- -- -- --
-
Which has Higher Returns XTLB or PHGE?
BiomX, Inc. has a net margin of -341.36% compared to XTL Biopharmaceuticals Ltd.'s net margin of --. XTL Biopharmaceuticals Ltd.'s return on equity of -34.34% beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About XTLB or PHGE?
XTL Biopharmaceuticals Ltd. has a consensus price target of --, signalling upside risk potential of 4356.33%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 8150%. Given that BiomX, Inc. has higher upside potential than XTL Biopharmaceuticals Ltd., analysts believe BiomX, Inc. is more attractive than XTL Biopharmaceuticals Ltd..
Company Buy Ratings Hold Ratings Sell Ratings XTLBXTL Biopharmaceuticals Ltd.0 0 0 PHGEBiomX, Inc.1 0 0 -
Is XTLB or PHGE More Risky?
XTL Biopharmaceuticals Ltd. has a beta of 1.174, which suggesting that the stock is 17.404% more volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.
-
Which is a Better Dividend Stock XTLB or PHGE?
XTL Biopharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XTL Biopharmaceuticals Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XTLB or PHGE?
XTL Biopharmaceuticals Ltd. quarterly revenues are $162K, which are larger than BiomX, Inc. quarterly revenues of --. XTL Biopharmaceuticals Ltd.'s net income of -$553K is higher than BiomX, Inc.'s net income of -$9.2M. Notably, XTL Biopharmaceuticals Ltd.'s price-to-earnings ratio is -- while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XTL Biopharmaceuticals Ltd. is 11.98x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XTLBXTL Biopharmaceuticals Ltd.11.98x -- $162K -$553K PHGEBiomX, Inc.-- -- -- -$9.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
